Wegovy Oral Pill Launches in Germany, Expands Globally as Competition Intensifies Against Eli Lilly

# Wegovy Goes Global: China Filing, Germany Launch & the Battle for Oral GLP-1 Dominance **Episode Description:** Wegovy is making headlines again — and this week's episode breaks down exactly why. From a major regulatory filing in China to the first-ever EU launch of oral Wegovy in Germany, Novo Nordisk's obesity drug is rapidly transforming from a blockbuster injection into a global oral franchise. In this episode, we cover: - **China's regulatory green light** — Novo Nordisk's oral Wegovy application has been accepted by China's drug regulator, opening access to one of the world's largest pharmaceutical markets and intensifying competition with Eli Lilly's obesity drug lineup. - **Germany's historic launch** — Oral Wegovy hits German pharmacies on September 1, making Germany the first EU country to offer the pill form of this weight loss treatment. - **UK rollout update** — With roughly 300,000 UK patients already on oral Wegovy, we look at how Eli Lilly's rival pill, Foundayo, is heating up the GLP-1 competition across Europe. - **US pricing and access battles** — Medicare's $50/month Bridge program is gaining real traction through CVS and Walgreens, while a proposed $245 Medicaid price point adds fuel to the ongoing obesity drug affordability debate. - **Clinical pipeline news** — Novo Nordisk's new OASIS 5 study is exploring lower maintenance doses of oral Wegovy, aiming to balance weight loss efficacy with improved tolerability. - **Market and economic ripple effects** — From Denmark raising its 2026 growth forecast because of Wegovy's success to PepsiCo dropping employee coverage, we unpack how insurance decisions and investor sentiment are shaping the future of obesity treatment. Whether you're tracking pharmaceutical stocks, following GLP-1 dr Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai